SG10201601507YA - Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases - Google Patents

Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Info

Publication number
SG10201601507YA
SG10201601507YA SG10201601507YA SG10201601507YA SG10201601507YA SG 10201601507Y A SG10201601507Y A SG 10201601507YA SG 10201601507Y A SG10201601507Y A SG 10201601507YA SG 10201601507Y A SG10201601507Y A SG 10201601507YA SG 10201601507Y A SG10201601507Y A SG 10201601507YA
Authority
SG
Singapore
Prior art keywords
diseases
treatment
novel compounds
control disorders
breathing control
Prior art date
Application number
SG10201601507YA
Other languages
English (en)
Inventor
Scott L Dax
Richard Woodward
Sean Peng
Original Assignee
Galleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals Inc filed Critical Galleon Pharmaceuticals Inc
Publication of SG10201601507YA publication Critical patent/SG10201601507YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0465—Tracheostomy tubes; Devices for performing a tracheostomy; Accessories therefor, e.g. masks, filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201601507YA 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases SG10201601507YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41777710P 2010-11-29 2010-11-29
US201161494268P 2011-06-07 2011-06-07

Publications (1)

Publication Number Publication Date
SG10201601507YA true SG10201601507YA (en) 2016-04-28

Family

ID=46162783

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601507YA SG10201601507YA (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
SG2013041439A SG190921A1 (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013041439A SG190921A1 (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Country Status (11)

Country Link
US (2) US9351972B2 (cg-RX-API-DMAC7.html)
EP (1) EP2646423A4 (cg-RX-API-DMAC7.html)
JP (1) JP5907986B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140049961A (cg-RX-API-DMAC7.html)
CN (1) CN103347866B (cg-RX-API-DMAC7.html)
AU (1) AU2011336764B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013013429A2 (cg-RX-API-DMAC7.html)
CA (1) CA2819333A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201601507YA (cg-RX-API-DMAC7.html)
WO (1) WO2012074999A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201303960B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PT2448582T (pt) 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2575710T3 (es) 2011-09-22 2016-06-30 Pfizer Inc Derivados de pirrolopirimidina y purina
SI2800743T1 (en) 2012-01-06 2018-08-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and methods for their use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
HK1209118A1 (en) * 2012-05-29 2016-03-24 Galleon Pharmaceuticals, Inc. Novel compounds and compositions for treatment of breathing control disorders or diseases
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
JP2015537032A (ja) * 2012-11-15 2015-12-24 ガリオン ファーマシューティカルズ インコーポレイテッド 経口バイオアベイラビリティーを有する呼吸制御調節化合物およびそれを使用する方法
WO2014151462A1 (en) * 2013-03-15 2014-09-25 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of using same
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
NZ715738A (en) 2013-07-11 2021-06-25 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN112159391A (zh) 2014-03-14 2021-01-01 阿吉奥斯制药公司 治疗活性化合物的药物组合物
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
KR102207539B1 (ko) * 2015-06-30 2021-01-26 네우라드 리미티드 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
HUE057263T2 (hu) 2015-10-15 2022-04-28 Servier Lab Kombinációs terápia rosszindulató betegségek kezelésére
EP3362065B1 (en) 2015-10-15 2024-04-03 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
JP2020536045A (ja) 2017-01-17 2020-12-10 デイヴィッド フォレスト マイケル Ａｔｐ合成酵素のリバースモードの治療的阻害剤
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
EP3688770A1 (en) * 2017-09-28 2020-08-05 Koninklijke Philips N.V. System and method for detecting stroke in patients during pressure support therapy
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3141612A1 (en) * 2019-05-22 2020-11-26 Enalare Therapeutics Inc. Methods and pharmaceutical compositions to treat drug overdose
KR20240004887A (ko) * 2021-05-04 2024-01-11 에날레어 테라퓨틱스 인크. 고전도도의 칼륨 채널 조정제, 이의 조성물, 이의 제조 방법, 및 이의 사용 방법
US12138267B2 (en) 2021-11-02 2024-11-12 Enalare Therapeutics Inc. Methods of treating respiratory depression modulated by a non-opioid agent
EP4456900A4 (en) * 2021-12-27 2025-12-24 Enalare Therapeutics Inc RESPIRATORY STIMULATING PARENTERAL FORMULATIONS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB1001665A (en) 1961-06-05 1965-08-18 American Cyanamid Co Triazine derivatives and process for their preparation
DE69027440T2 (de) 1989-10-11 1997-02-06 Teijin Ltd Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
JPH08272059A (ja) 1995-03-31 1996-10-18 Fuji Photo Film Co Ltd 多層ハロゲン化銀カラー写真感光材料包装体
JPH09189973A (ja) * 1996-01-08 1997-07-22 Fuji Photo Film Co Ltd ハロゲン化銀乳剤及びこれを用いる写真感光材料
JPH09251197A (ja) 1996-03-15 1997-09-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH09304898A (ja) 1996-05-15 1997-11-28 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
IL143929A0 (en) * 1999-01-22 2002-04-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
AU2457201A (en) * 1999-12-28 2001-07-09 Bristol-Myers Squibb Company Cytokine, especially tnf-alpha, inhibitors
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
HUP0401712A3 (en) * 2001-06-26 2009-06-29 Bristol Myers Squibb Co N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
BR0212895A (pt) * 2001-09-21 2005-05-10 Reddy Us Therapeutics Inc Métodos e composições de novos compostos de triazina
US20030168629A1 (en) * 2001-12-10 2003-09-11 Lazar Warren G. Reactive liquid polymer crosslinking agent and process for preparation
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
MXPA04010983A (es) 2002-05-06 2005-02-14 Genelabs Tech Inc Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
TW200418498A (en) 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US7384937B2 (en) 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
CN1826328A (zh) * 2003-07-22 2006-08-30 神经能质公司 经取代的吡啶－2－基胺类似物
CN1926140A (zh) * 2004-03-05 2007-03-07 大正制药株式会社 吡咯并嘧啶衍生物
WO2005090469A1 (en) 2004-03-15 2005-09-29 Honeywell International Inc. Cellulose reinforced resin compositions
WO2006023702A2 (en) 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
CN101495464B (zh) * 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂
US8227466B2 (en) * 2006-05-17 2012-07-24 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2059512A1 (en) * 2006-08-01 2009-05-20 Praecis Pharmaceuticals Incorporated P38 kinase inhibitors
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
JP2010509233A (ja) * 2006-11-03 2010-03-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
CN101885707B (zh) * 2009-05-15 2012-08-29 中国科学院化学研究所 三嗪类衍生物及其制备方法与作为杀虫剂的用途

Also Published As

Publication number Publication date
EP2646423A4 (en) 2014-04-30
WO2012074999A1 (en) 2012-06-07
AU2011336764A1 (en) 2013-06-20
JP5907986B2 (ja) 2016-04-26
CN103347866A (zh) 2013-10-09
US20160256463A1 (en) 2016-09-08
CA2819333A1 (en) 2012-06-07
JP2013544285A (ja) 2013-12-12
CN103347866B (zh) 2016-05-18
ZA201303960B (en) 2014-07-30
KR20140049961A (ko) 2014-04-28
US9351972B2 (en) 2016-05-31
AU2011336764B2 (en) 2017-02-23
BR112013013429A2 (pt) 2017-03-21
EP2646423A1 (en) 2013-10-09
SG190921A1 (en) 2013-07-31
US20120142647A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
ZA201303960B (en) Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
ZA201205829B (en) Treatment of respiratory disorders
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
IL230458A0 (en) Compounds for the treatment and prevention of respiratory syncytial viral disease
IL225668A0 (en) The compositions for the treatment of disorders in the upper respiratory tract
ZA201301601B (en) Treatment of diseases
ZA201501390B (en) Compounds for the treatment of mtor pathway related diseases
IL260078B (en) Therapy used to treat Gaucher disease
EP2855438A4 (en) Novel compounds and compositions for the treatment of respiratory disorders or diseases
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
ZA201207696B (en) Compound for treatment of respiratory condition or disease
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
ZA201104663B (en) Sulfonamide compounds for the treatment of respiratory disorders
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
HK1182325A (en) Compound for treatment of respiratory condition or disease
GB201001912D0 (en) Treatment of respiratory disorders
AU2010901601A0 (en) Compound for the treatment of respiratory condition or disease
GB201002841D0 (en) Treatment of inflammatory respiratory disease
GB201019482D0 (en) Compounds for the treatment of metabolic disorders
GB201004742D0 (en) Compounds for the treatment of metabolic disorders
GB201004740D0 (en) Compounds for the treatment of metabolic disorders
GB201006164D0 (en) Compounds for the treatment of metabolic disorders